FDA accepts investigational new drug application for Eluminex DME treatment
Click Here to Manage Email Alerts
Key takeaways:
- EB-105 is a trispecific fusion antibody for the treatment of diabetic macular edema.
- Eluminex is seeking strategic alliances to support its programs for retinal disease.
The FDA accepted an investigational new drug application for a trispecific fusion antibody for the treatment of diabetic macular edema, according to a press release from Eluminex Biosciences.
EB-105 targets VEGF-A, VEGF-B, placental growth factor, angiopoietin-2 and interleukin-6 (IL-6) receptor for the treatment of DME.
In the release, Quan Dong Nguyen, MD, MSc, FARVO, FASRS, said elevated levels of IL-6 are well documented in patients with DME and can contribute to inflammation and vascular permeability in other retinal diseases such as neovascular age-related macular degeneration.
“High levels of IL-6 may likely be the reason for persistent refractory edema in DME patients being treated with current agents such as aflibercept and faricimab,” Nguyen said in the release. “The ability to inhibit several biological pathways simultaneously with a single agent offers compelling potential for further incremental benefits in patients with retinal diseases.”
Eluminex is in the process of forming investment partnerships and alliances to support its initiatives in retinal disease and dermal facial aesthetics.
Click Here to Manage Email Alerts